256 related articles for article (PubMed ID: 34344444)
1. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity.
Cutolo M; Gotelli E; Montagna P; Tardito S; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
Arthritis Res Ther; 2021 Aug; 23(1):205. PubMed ID: 34344444
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
[TBL] [Abstract][Full Text] [Related]
3. Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay.
Cutolo M; Soldano S; Montagna P; Trombetta AC; Contini P; Ruaro B; Sulli A; Scabini S; Stratta E; Paolino S; Pizzorni C; Smith V; Brizzolara R
Arthritis Res Ther; 2018 Jul; 20(1):157. PubMed ID: 30053831
[TBL] [Abstract][Full Text] [Related]
4. Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
Cutolo M; Ruaro B; Montagna P; Brizzolara R; Stratta E; Trombetta AC; Scabini S; Tavilla PP; Parodi A; Corallo C; Giordano N; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
Arthritis Res Ther; 2018 May; 20(1):77. PubMed ID: 29720235
[TBL] [Abstract][Full Text] [Related]
5. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
7. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
8. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
10. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
[TBL] [Abstract][Full Text] [Related]
11. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
[TBL] [Abstract][Full Text] [Related]
12. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
14. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
Mathai SK; Gulati M; Peng X; Russell TR; Shaw AC; Rubinowitz AN; Murray LA; Siner JM; Antin-Ozerkis DE; Montgomery RR; Reilkoff RA; Bucala RJ; Herzog EL
Lab Invest; 2010 Jun; 90(6):812-23. PubMed ID: 20404807
[TBL] [Abstract][Full Text] [Related]
15. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
16. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
18. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X
Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
